Invesco India Pharma and Healthcare Fund vs LIC MF Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
Invesco India Pharma and Healthcare Fund is a Sectoral fund and LIC MF Healthcare Fund is a Thematic fund. Invesco India Pharma and Healthcare Fund charges 3.30% a year and LIC MF Healthcare Fund 1.38% (Direct plans). Their portfolios overlap 40.2%: they hold 9 of the same securities.
Invesco India Pharma and Healthcare Fund
Sectoral
- Expense ratio
- 3.30%
- NAV
- ₹9.66
Which is better, Invesco India Pharma and Healthcare or LIC MF Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- LIC MF Healthcare costs less: 1.38% a year against 3.30% (Direct plans).
- LIC MF Healthcare fell less in its worst fall since 10-09-2026: −10.5% against −11.4%.
- Invesco India Pharma and Healthcare is the larger fund: ₹436 Cr against ₹99 Cr.
- Their portfolios overlap 40.2%: 9 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Invesco India Pharma and Healthcare Fund | LIC MF Healthcare Fund |
|---|---|---|
| Fund house | Invesco Mutual Fund | LIC Mutual Fund |
| Category | Sectoral | Thematic |
| AUM | ₹436 Cr (30-09-2026) | ₹99 Cr (30-09-2026) |
| NAV | ₹9.66 (Direct) | ₹36.37 (Direct) |
| Expense ratio (Direct) | 3.30% | 1.38% |
| Expense ratio (Regular) | 5.19% | 2.68% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 01-09-2026 | 28-02-2019 |
| Minimum investment | Not available | ₹5,000 |
| Lock in | None | None |
| Fund managers | Aditya Khemani | Sudhanshu Asthana, Dhaval Sangoi |
| Exit load | Exit load of 0.50%, if redeemed within 3 months. | Nil, If units of the Scheme are redeemed or switched out up to 12% of the units (the limit) within 90 days from the date of allotment. 1% of the applicable NAV, If units of the scheme are redeemed or switched out in excess of the limit within 90 days from the date of allotment. Nil, If units of scheme are redeemed or switched out after 90 days from the date of allotment. |
Invesco India Pharma and Healthcare vs LIC MF Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Invesco India Pharma and Healthcare Fund (Direct) | +0.73% | -- | -- | -- | -- | -- | -- |
| LIC MF Healthcare Fund (Direct) | −0.28% | −0.59% | +12.42% | +10.96% | +22.45% | -- | -- |
| Sectoral average | −1.70% | -- | -- | -- | -- | -- | -- |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | -- | -- |
Category average: the average of the 20 Sectoral funds and the 235 Thematic funds, same plan type.
Invesco India Pharma and Healthcare vs LIC MF Healthcare: Year-wise Returns
| Year | Invesco India Pharma andInvesco India Pharma and Healthcare | LIC MFLIC MF Healthcare | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | -- | +13.82% | +15.08% |
| 2025 | -- | −3.21% | −2.72% |
| 2024 | -- | +43.90% | +44.30% |
Invesco India Pharma and Healthcare vs LIC MF Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Invesco India Pharma and Healthcare vs LIC MF Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Invesco India Pharma and Healthcare Fund (Direct) | LIC MF Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | −23.45% | +19.73% |
| Standard deviation | 18.70% | 13.85% |
| Sharpe ratio | -1.54 | 0.98 |
| Sortino ratio | -2.20 | 1.39 |
| Maximum drawdown | −11.4% (23-10-2026) | −15.1% (28-02-2025) |
| Beta | 1.00 | 0.94 |
| Alpha | −8.00% | −0.06% |
From daily NAVs, 10-09-2026 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Invesco India Pharma and Healthcare Fund (Direct)
LIC MF Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Invesco India Pharma and Healthcare Fund (Direct) | −11.4% | 23-09-2026 | 23-10-2026 | Not yet | -- | −4.4% |
| LIC MF Healthcare Fund (Direct) | −10.5% | 23-09-2026 | 23-10-2026 | Not yet | -- | −4.9% |
| BSE Healthcare TRI | −9.9% | 23-09-2026 | 23-10-2026 | Not yet | -- | −3.8% |
From daily values since 10-09-2026, the first day every fund has.
Invesco India Pharma and Healthcare vs LIC MF Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Invesco India Pharma and Healthcare Fund, September 2026; LIC MF Healthcare Fund, September 2026
Holdings in common
- Overlap
- 40.2%
- Held by both
- 9
- Only in Invesco India Pharma and Healthcare
- 4
- Only in LIC MF Healthcare
- 16
| Security | % of Invesco India Pharma and Healthcare | % of LIC MF Healthcare |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 8.99% | 9.59% |
| Divi's Laboratories Limited | 7.85% | 9.07% |
| Apollo Hospitals Enterprise Limited | 8.03% | 5.75% |
| Torrent Pharmaceuticals Limited | 4.93% | 6.04% |
| Max Healthcare Institute Limited | 9.58% | 2.99% |
| Glenmark Pharmaceuticals Limited | 4.86% | 2.61% |
| Global Health Limited | 7.00% | 2.59% |
| Dr Agarwals Health Care Limited | 6.32% | 2.46% |
| Aster DM Quality Care Limited | 1.99% | 4.61% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 40.2% means 40.2% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Invesco India Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Sai Life Sciences Limited | 8.63% |
| Manipal Health Enterprises Ltd | 7.98% |
| Corona Remedies Limited | 6.13% |
| Krishna Institute Of Medical Sciences Limited | 4.72% |
Largest holdings only in LIC MF Healthcare Fund
| Security | % of fund |
|---|---|
| Neuland Laboratories Ltd. | 6.14% |
| Aurobindo Pharma Ltd. | 5.23% |
| Navin Fluorine International Ltd. | 4.98% |
| Zydus Lifesciences Ltd. | 4.97% |
| Fortis Healthcare Ltd. | 3.77% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Invesco India Pharma and Healthcare | LIC MF Healthcare |
|---|---|---|
| Equity | 87.0% | 97.5% |
| Debt | 0.0% | 0.0% |
| Cash and others | 13.0% | 2.5% |
Market cap of stocks
| Market cap | Invesco India Pharma and Healthcare | LIC MF Healthcare |
|---|---|---|
| Large Cap | 29.8% | 30.4% |
| Mid Cap | 16.4% | 32.0% |
| Small Cap | 32.8% | 35.1% |
| Not on AMFI's list | 8.0% | 0.0% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Invesco India Pharma and Healthcare | LIC MF Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 41.4% | 61.3% |
| Healthcare Services | 45.6% | 31.2% |
| Chemicals & Petrochemicals | 0.0% | 5.0% |
The six largest sectors of each fund's stocks, % of the fund.
Invesco India Pharma and Healthcare vs LIC MF Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Invesco India Pharma and Healthcare Fund | LIC MF Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 3.30% | 1.38% |
| Base expense ratio (Direct) | 0.50% | 0.97% |
| Total expense ratio (Regular) | 5.19% | 2.68% |
| Base expense ratio (Regular) | 2.10% | 2.10% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Invesco India Pharma and Healthcare with
- Invesco India Pharma and Healthcare vs DSP Healthcare
- Invesco India Pharma and Healthcare vs Nippon India Pharma
- Invesco India Pharma and Healthcare vs Bandhan Transportation and Logistics
- Invesco India Pharma and Healthcare vs Nippon India Power & Infra
- Invesco India Pharma and Healthcare vs Invesco India Financial Services
Invesco India Pharma and Healthcare Fund vs LIC MF Healthcare Fund: Frequently Asked Questions
What is the difference between Invesco India Pharma and Healthcare Fund and LIC MF Healthcare Fund?
Invesco India Pharma and Healthcare Fund is a Sectoral fund, LIC MF Healthcare Fund is a Thematic fund, run by Invesco Mutual Fund and LIC Mutual Fund. Their portfolios overlap 40.2%. Invesco India Pharma and Healthcare Fund charges 3.30% a year and LIC MF Healthcare Fund 1.38%.
Which has the lower expense ratio, Invesco India Pharma and Healthcare Fund or LIC MF Healthcare Fund?
LIC MF Healthcare Fund charges less: 1.38% a year against 3.30%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Invesco India Pharma and Healthcare Fund and LIC MF Healthcare Fund overlap?
40.2%. They hold 9 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, APOLLOHOSP. From each fund's latest monthly portfolio.
Which is riskier, Invesco India Pharma and Healthcare Fund or LIC MF Healthcare Fund?
On SEBI's riskometer, Invesco India Pharma and Healthcare Fund is rated Very High and LIC MF Healthcare Fund Very High. Over their common history, the standard deviation of daily returns was 18.70% and 13.85% a year.
Can I invest in both Invesco India Pharma and Healthcare Fund and LIC MF Healthcare Fund?
Yes. 40.2% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Invesco India Pharma and Healthcare Fund and LIC MF Healthcare Fund?
Invesco India Pharma and Healthcare Fund: Aditya Khemani. LIC MF Healthcare Fund: Sudhanshu Asthana, Dhaval Sangoi.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.